Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Kent C. Shih, Manish R. Patel, Nicholas A. Butowski, Gerald Steven Falchook, Sani Haider Kizilbash, Suzanne Fields Jones, Jeffrey A. Bacha, Dennis Brown, Richard Stephen Schwartz, Sarath Kanekal, John C.I. Constant, Howard A. Burris | ||||||||||||
Title | Dianhydrogalactitol in bevacizumab-refractory GBM: Further analysis of a phase 1-2 trial. | ||||||||||||
|
|||||||||||||
URL | http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.2061 | ||||||||||||
Abstract Text | Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 2061-2061 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
VAL-083 | Dianhydrogalactitol|VAL083|VAL 083 | Dianhydrogalactitol (VAL-083) is a DNA cross-linking agent which has shown anti-tumor activities in clinical settings (Journal of Clinical Oncology 36, no. 15_suppl., PMID: 6784907). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|